1. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study.
Mov Disord 2006;21:916-23.
2. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Ray Chaudhuri K; on behalf of the NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease.
Mov Disord 2011;26:399-406.
3. Kwon DY, Koh SB, Lee JH, Park HK, Kim HJ, Shin HW, et al. The KMDS-NATION study: Korean movement disorders and quality of life in Parkinson’s disease.
J Clin Neurol 2016;12:393-402.
4. Sauerbier A, Jitkritsadakul O, Titova N, Klingelhoefer L, Tsuboi Y, Carr H, et al. Non-motor symptoms assessed by non-motor symptoms questionnaire and non-motor symptoms scale in Parkinson’s disease in selected Asian populations.
Neuroepidemiology 2017;49:1-17.
5. Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations.
Mov Disord 2007;22:1077-1092.
6. Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, Grill S, et al. A comparison of nine scales to detect depression in Parkinson disease: which scale to use?
Neurology 2012;78:998-1006.
7. Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinson’s disease: a critical review updating recent literature.
J Affect Disord 2015;184:216-224.
8. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations.
Mov Disord 2008;23:2015-2025.
9. Dissanayaka NNW, Torbey E, Pachana NA. Anxiety rating scales in Parkinson’s disease: a critical review updating recent literature.
Int Psychogeriatr 2015;27:1777-1784.
10. Mondolo F, Jahanshahi M, Granà A, Biasutti E, Cacciatori E, Di Benedetto P. Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales.
Neurol Sci 2007;28:270-275.
11. Forjaz MJ, How to evaluate validation data. How to evaluate validation data. In: Sampaio C, Goetz CG, Schrag A, eds. Rating scales in Parkinson’s disease: clinical practice and research. New York: Oxford University Press, 2012;16-41.
12. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study.
Qual Life Res 2010;19:539-549.
13. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?
Arthritis Rheum 2007;57:1358-1362.
14. Cappelleri JC, Jason Lundy J, Hays RD. Overview of classical test theory and item response theory for the quantitative assessment of items in developing patient-reported outcomes measures.
Clin Ther 2014;36:648-662.
15. Riley WT, Pilkonis P, Cella D. Application of the National Institutes of Health Patient-reported Outcome Measurement Information System (PROMIS
®) to mental health research.
J Ment Health Policy Econ 2011;14:201-208.
16. Forjaz MJ, Rodriguez-Blázquez C, Martinez-Martin P. Rasch analysis of the hospital anxiety and depression scale in Parkinson’s disease.
Mov Disord 2009;24:526-532.
17. da Rocha NS, Chachamovich E, de Almeida Fleck MP, Tennant A. An introduction to Rasch analysis for psychiatric practice and research.
J Psychiatr Res 2013;47:141-148.
18. Forjaz MJ, Ayala A, Rodriguez-Blazquez C, Frades-Payo B, Martinez-Martin P. Assessing autonomic symptoms of Parkinson’s disease with the SCOPA-AUT: a new perspective from Rasch analysis.
Eur J Neurol 2010;17:273-279.
19. Kletzel SL, Hernandez JM, Miskiel EF, Mallinson T, Pape TL. Evaluating the performance of the montreal cognitive assessment in early stage Parkinson’s disease.
Parkinsonism Relat Disord 2017;37:58-64.
20. Yang HJ, Ahn JH, Lee J, Lee WK, Lee J, Kim Y. Measuring anxiety in patients with early-stage Parkinson’s disease: Rasch analysis of the state-trait anxiety inventory.
Front Neurol 2019;10:49.
21. Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure.
Neurology 2007;69:555-563.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale.
Acta Psychiatr Scand 1983;67:361-370.
23. Oh SM, Min KJ, Park DB. A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. J Korean Neuropsychiatr Assoc 1999;38:289-296.
24. Schade S, Mollenhauer B, Trenkwalder C. Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide.
Mov Disord Clin Pract 2020;7:343-345.
25. Mondolo F, Jahanshahi M, Granà A, Biasutti E, Cacciatori E, Di Benedetto P. The validity of the hospital anxiety and depression scale and the geriatric depression scale in Parkinson’s disease.
Behav Neurol 2006;17:109-115.
26. Chiang KS, Green KE, Cox EO. Rasch analysis of the geriatric depression scale-short form.
Gerontologist 2009;49:262-275.
27. Li CY, Romero S, Bonilha HS, Simpson KN, Simpson AN, Hong I, et al. Linking existing instruments to develop an activity of daily living item bank.
Eval Health Prof 2016;41:25-43.
28. Khadka J, Gothwal VK, McAlinden C, Lamoureux EL, Pesudovs K. The importance of rating scales in measuring patient-reported outcomes.
Health Qual Life Outcomes 2012;10:80.
29. Kreijns K, Bijker M, Weidlich J. A Rasch Analysis Approach to the Development and Validation of a Social Presence Measure. In: Khine MS, ed. Rasch Measurement: Applications in quantitative educational research. Singapore: Springer Nature, 2020;197-221.
30. Linacre JM. Optimizing rating scale category effectiveness.
J Appl Meas 2002;3:85-106.
31. Janssen KC, Phillipson S, O’Connor J, Johns MW. Validation of the Epworth sleepiness scale for children and adolescents using Rasch analysis.
Sleep Med 2017;33:30-35.
32. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease.
Parkinsonism Relat Disord 2002;8:193-197.
33. Rodriguez-Blázquez C, Frades-Payo B, Forjaz MJ, de Pedro-Cuesta J, Martinez-Martin P; Longitudinal Parkinson’s Disease Patient Study Group. Psychometric attributes of the hospital anxiety and depression scale in Parkinson’s disease.
Mov Disord 2009;24:519-525.